Sareum announced this week that its application for two Phase 1 clinical trials under its CHK 1 inhibitor programme, had received regulatory approval and that dosing is expected to begin during the current quarter. We understand that the collaboration with the CRT Pioneer Fund is seeking to license the candidate to a larger partner either during or after the Phase 1 dose escalation study.
